Press Releases

Date Title and Summary Additional Formats
Toggle Summary CORRECTION: Radius Health Announces Plans for Global Prader-Willi Syndrome Pivotal Study
FDA Type C meeting minutes provide clarity on the Phase 2/3 study design for RAD011 505(b)(2) regulatory strategy: acceptable approach upon completion of PK & food effect studies Based on results, a single well controlled study could serve as the basis for marketing approval RAD011 had previously
View HTML
Toggle Summary FDA Accepts IND Application for Radius Health's Investigational Drug RAD1901 Being Developed for Potential Use in Metastatic Breast Cancer
WALTHAM, Mass. , Dec. 19, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's Investigational New Drug (IND) application for its investigational drug RAD1901, a tissue-selective estrogen receptor
View HTML
Toggle Summary FDA Approves Radius Health's TYMLOS™ (abaloparatide), a Bone Building Agent for the Treatment of Postmenopausal Women with Osteoporosis at High Risk for Fracture
TYMLOS is the first new anabolic (bone building) agent for postmenopausal women with osteoporosis in the United States in nearly 15 years US Commercial Launch in May Approval Based on Results at 18 months from the Landmark ACTIVE Trial and the first six months of ACTIVExtend Trial Nearly One in Two
View HTML
Toggle Summary Fractured Truth Campaign Wins Bronze Pearl Award for Content Marketing Excellence in the Healthcare/Pharmaceutical Industry
      WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq:RDUS) today announced that Fractured Truth—an unbranded patient campaign aimed to educate younger postmenopausal women about risks associated with osteoporosis—won the Bronze Healthcare/Pharmaceutical Industry Pearl
View HTML
Toggle Summary Investigational Drug Abaloparatide Reduces the Incidence of Fractures in Postmenopausal Women With Osteoporosis
Radius Health announces positive Phase 3 data from the ACTIVExtend trial presented at the American Society for Bone and Mineral Research (ASBMR) 2015 Annual Meeting First six months of top-line data from ACTIVExtend show that treatment with investigational drug abaloparatide-SC followed by
View HTML
Toggle Summary JAMA Publishes Positive Phase 3 Data for Abaloparatide in Postmenopausal Women With Osteoporosis
Results from Phase 3 ACTIVE trial show abaloparatide significantly reduced the incidence of new vertebral fractures and nonvertebral fractures in postmenopausal women with osteoporosis at 18 months when compared with placebo
View HTML
Toggle Summary Mayo Clinic Proceedings Publishes Positive Results from the ACTIVExtend Clinical Trial of Abaloparatide-SC in Postmenopausal Women With Osteoporosis
— Results from interim analysis of the ACTIVExtend study of postmenopausal women with osteoporosis treated for 18 months with investigational drug abaloparatide-SC in the ACTIVE trial who were transitioned to alendronate in ACTIVExtend show statistically significant reductions at six months in the
View HTML
Toggle Summary Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.
View HTML
Toggle Summary Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
Study met both primary endpoints in patients with ER+/HER2- advanced or mBC Elacestrant becomes the first oral SERD with positive topline results in pivotal study as a monotherapy versus SoC for the treatment of ER+/HER2- advanced or mBC Elacestrant extended PFS in the overall population and the
View HTML
Toggle Summary New Analysis from ACTIVE Showed Consistent Fracture Reductions for Abaloparatide-SC Across Geographies
The data was presented in an Oral Late-Breaker at Annual Endocrine Society Meeting "ENDO 2017" on April 1 Additional analysis of BMD gains at the wrist and fracture reductions  at the ultradistal radius compared to placebo and teriparatide were presented on April 2 WALTHAM, Mass., April 03, 2017
View HTML